OccuRx

OccuRx is a biopharmaceutical company focused on innovative therapeutic strategies for ocular diseases associated with inflammation and fibrosis. OccuRx has identified and validated a series of leading candidates for novel targets and established preclinical proof of concept for the treatment and prevention of ocular fibrosis. The company is leveraging these proprietary small molecule drugs to address unmet clinical needs with more targeted ophthalmic therapies to improve vision and prevent vision loss in inflammatory and degenerative eye diseases. OCX063, our most advanced lead product candidate, is a small molecule drug with the potential to inhibit the growth of new and abnormal blood vessels and reduce retinal neuronal inflammation.